Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raffit Hassan

Showing results (41-50 of 150) with videos related to

Pageof 15
Sort By:
International Journal of Cancer|February 11, 2012
Efficacy of anti-insulin-like growth factor I receptor monoclonal antibody cixutumumab in mesothelioma is highly correlated with insulin growth factor-I receptor sites/cellNeetu Kalra, Jingli Zhang, Yunkai Yu, et al.
Oncology Reports|March 20, 2012
Patients with peritoneal mesothelioma lack epidermal growth factor receptor tyrosine kinase mutations that would make them sensitive to tyrosine kinase inhibitorsNeetu Kalra, Ali Ashai, Liqiang Xi, et al.
Cancer Chemotherapy and Pharmacology|February 23, 2016
Population pharmacokinetics and exposure-response relationship of amatuximab, an anti-mesothelin monoclonal antibody, in patients with malignant pleural mesothelioma and its application in dose selectionAnubha Gupta, Ziad Hussein, Raffit Hassan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2016
Mesothelin Immunotherapy for Cancer: Ready for Prime Time?Raffit Hassan, Anish Thomas, Christine Alewine, et al.
American Journal of Clinical Oncology|June 6, 2008
Malignant mesothelioma of the inguinal canal with an unusually long survivalJanice M Walshe, Anthony Gal, Douglas R Murray, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2016
Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient-Derived Xenografts and Mesothelin as a Biomarker of Tumor ResponseJingli Zhang, Swati Khanna, Qun Jiang, et al.
Medrxiv : the Preprint Server for Health Sciences|December 31, 2025
Urinary Metabolites and Survival in Malignant MesotheliomaLeila Toulabi, Joshua K Stone, Mohammed Khan, et al.
Scientific Reports|May 22, 2015
New high affinity monoclonal antibodies recognize non-overlapping epitopes on mesothelin for monitoring and treating mesotheliomaYi-Fan Zhang, Yen Phung, Wei Gao, et al.
The Journal of Biological Chemistry|December 17, 2008
A binding domain on mesothelin for CA125/MUC16Osamu Kaneko, Lucy Gong, Jingli Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2018
Reply to D. de Fonseka et alHedy L Kindler, Valerie Rusch, Raphael Bueno, et al.
Pageof 15

Showing results (41-50 of 150) with videos related to

Sort By:
Pageof 15
International Journal of Cancer|February 11, 2012
Efficacy of anti-insulin-like growth factor I receptor monoclonal antibody cixutumumab in mesothelioma is highly correlated with insulin growth factor-I receptor sites/cellNeetu Kalra, Jingli Zhang, Yunkai Yu, et al.
Oncology Reports|March 20, 2012
Patients with peritoneal mesothelioma lack epidermal growth factor receptor tyrosine kinase mutations that would make them sensitive to tyrosine kinase inhibitorsNeetu Kalra, Ali Ashai, Liqiang Xi, et al.
Cancer Chemotherapy and Pharmacology|February 23, 2016
Population pharmacokinetics and exposure-response relationship of amatuximab, an anti-mesothelin monoclonal antibody, in patients with malignant pleural mesothelioma and its application in dose selectionAnubha Gupta, Ziad Hussein, Raffit Hassan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2016
Mesothelin Immunotherapy for Cancer: Ready for Prime Time?Raffit Hassan, Anish Thomas, Christine Alewine, et al.
American Journal of Clinical Oncology|June 6, 2008
Malignant mesothelioma of the inguinal canal with an unusually long survivalJanice M Walshe, Anthony Gal, Douglas R Murray, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2016
Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient-Derived Xenografts and Mesothelin as a Biomarker of Tumor ResponseJingli Zhang, Swati Khanna, Qun Jiang, et al.
Medrxiv : the Preprint Server for Health Sciences|December 31, 2025
Urinary Metabolites and Survival in Malignant MesotheliomaLeila Toulabi, Joshua K Stone, Mohammed Khan, et al.
Scientific Reports|May 22, 2015
New high affinity monoclonal antibodies recognize non-overlapping epitopes on mesothelin for monitoring and treating mesotheliomaYi-Fan Zhang, Yen Phung, Wei Gao, et al.
The Journal of Biological Chemistry|December 17, 2008
A binding domain on mesothelin for CA125/MUC16Osamu Kaneko, Lucy Gong, Jingli Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2018
Reply to D. de Fonseka et alHedy L Kindler, Valerie Rusch, Raphael Bueno, et al.
Pageof 15